Last reviewed 2026-04-22 · How we verify

BRII-196

BRII-196 is a monoclonal antibody that binds to the spike protein of SARS-CoV-2 to neutralize the virus and prevent infection.

BRII-196 is a monoclonal antibody that binds to the spike protein of SARS-CoV-2 to neutralize the virus and prevent infection. Used for COVID-19 treatment in adults and adolescents, COVID-19 post-exposure prophylaxis.

At a glance

Mechanism of action

BRII-196 is a fully human monoclonal antibody designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. By binding to this critical viral epitope, it prevents the virus from attaching to and entering human cells, thereby neutralizing viral infectivity. The antibody was developed through a collaboration between NIAID and Brii Biosciences for treatment and prevention of COVID-19.

Approved indications

• COVID-19 treatment in adults and adolescents
• COVID-19 post-exposure prophylaxis

Common side effects

• Infusion-related reactions
• Hypersensitivity reactions
• Injection site reactions

Key clinical trials

• ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2, PHASE3)
• BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
• ACTIV-3: Therapeutics for Inpatients With COVID-19 (PHASE3)
• SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine (PHASE4)
• A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 (PHASE1)
• A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19 (PHASE2)
• A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 (PHASE2)
• Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.